{"id":"fluticasone-propionate-salmeterol-combination-product","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-7","effect":"Nervousness/anxiety"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"2-5","effect":"Oral candidiasis"},{"rate":"3-8","effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL1201396","moleculeType":"Small molecule","molecularWeight":"444.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing sustained bronchodilation. The combination provides both rapid and sustained symptom relief with reduced inflammation in chronic obstructive airway diseases.","oneSentence":"Fluticasone propionate is a corticosteroid that reduces airway inflammation, while salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:38.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance treatment"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":"Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans","enrollment":35},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT04503460","phase":"PHASE4","title":"Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-07-23","conditions":"Asthma","enrollment":24},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427},{"nctId":"NCT05664061","phase":"PHASE3","title":"Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-01-30","conditions":"Asthma","enrollment":451},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02980133","phase":"PHASE3","title":"Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-12-28","conditions":"Asthma","enrollment":841},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02680561","phase":"PHASE1","title":"A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-04","conditions":"Asthma","enrollment":20},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT02024204","phase":"NA","title":"Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-04-09","conditions":"Lung Diseases, Medication Compliance","enrollment":60},{"nctId":"NCT01117116","phase":"NA","title":"Sub-Sensitivity to Long-Acting Bronchodilators (LABA)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2010-03","conditions":"Asthma","enrollment":21},{"nctId":"NCT02571777","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-08","conditions":"Asthma","enrollment":3092},{"nctId":"NCT03676413","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-10-02","conditions":"Asthma","enrollment":451},{"nctId":"NCT02554786","phase":"PHASE3","title":"A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-29","conditions":"Asthma","enrollment":2216},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT03755544","phase":"","title":"Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-01-16","conditions":"Asthma, Chronic Obstructive Pulmonary Disease","enrollment":231},{"nctId":"NCT03535870","phase":"NA","title":"Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)","status":"COMPLETED","sponsor":"West-Ward Pharmaceutical","startDate":"2018-04-26","conditions":"Asthma","enrollment":1556},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT01494610","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00118716","phase":"PHASE4","title":"A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-23","conditions":"Bronchospasm, Activity/Exercise Induced Bronchospasm","enrollment":248},{"nctId":"NCT03751202","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-11-20","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT00984659","phase":"PHASE4","title":"Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":366},{"nctId":"NCT01462344","phase":"PHASE4","title":"6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Asthma","enrollment":6250},{"nctId":"NCT01475721","phase":"PHASE4","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-18","conditions":"Asthma","enrollment":11751},{"nctId":"NCT00355342","phase":"PHASE4","title":"Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":186},{"nctId":"NCT00395304","phase":"PHASE3","title":"Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-03","conditions":"Asthma","enrollment":182},{"nctId":"NCT03562923","phase":"PHASE3","title":"A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-10","conditions":"Asthma","enrollment":1204},{"nctId":"NCT00353873","phase":"PHASE4","title":"Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-18","conditions":"Asthma","enrollment":506},{"nctId":"NCT03238482","phase":"PHASE1","title":"Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-08-16","conditions":"Asthma","enrollment":64},{"nctId":"NCT00273026","phase":"PHASE4","title":"Study In Asthma Control","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2004-11-08","conditions":"Asthma","enrollment":680},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02649478","phase":"NA","title":"Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2014-08","conditions":"Asthma","enrollment":1430},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT00315744","phase":"PHASE4","title":"Viapaed Study In Children And Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT00364442","phase":"PHASE1","title":"Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-28","conditions":"Asthma","enrollment":12},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76130},{"nctId":"NCT01332461","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":5677},{"nctId":"NCT02113436","phase":"PHASE4","title":"Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-01","conditions":"Asthma","enrollment":300},{"nctId":"NCT02260492","phase":"PHASE1","title":"Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma","status":"COMPLETED","sponsor":"Oriel Therapeutics","startDate":"2014-09","conditions":"Asthma","enrollment":879},{"nctId":"NCT01381406","phase":"","title":"Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3333},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01332344","phase":"","title":"Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":"Asthma","enrollment":5180},{"nctId":"NCT01337336","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT03169504","phase":"PHASE3","title":"Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2017-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":150},{"nctId":"NCT00291382","phase":"PHASE4","title":"Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Asthma","enrollment":150},{"nctId":"NCT01347060","phase":"","title":"Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Asthma","enrollment":17448},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1936},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT00497237","phase":"PHASE3","title":"Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-04","conditions":"Asthma","enrollment":382},{"nctId":"NCT00927758","phase":"PHASE2","title":"Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair","status":"COMPLETED","sponsor":"Sandoz","startDate":"2009-06","conditions":"Asthma","enrollment":105},{"nctId":"NCT00197106","phase":"PHASE4","title":"Treatment Of Symptomatic Asthma In Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06","conditions":"Asthma","enrollment":176},{"nctId":"NCT01751113","phase":"PHASE4","title":"A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":53},{"nctId":"NCT00461500","phase":"PHASE4","title":"SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Asthma","enrollment":81},{"nctId":"NCT00102882","phase":"PHASE4","title":"Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Asthma","enrollment":547},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT00361959","phase":"PHASE4","title":"SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1270},{"nctId":"NCT00549146","phase":"PHASE3","title":"Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":290},{"nctId":"NCT00115492","phase":"PHASE4","title":"Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":797},{"nctId":"NCT01192178","phase":"PHASE4","title":"Fall Epidemic Viral Pediatric Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Asthma","enrollment":339},{"nctId":"NCT00503009","phase":"PHASE4","title":"Study Of RV-39 In Patients Who Also Have Asthma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Asthma","enrollment":16},{"nctId":"NCT00441441","phase":"PHASE3","title":"A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Asthma","enrollment":351},{"nctId":"NCT00296491","phase":"PHASE4","title":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":725},{"nctId":"NCT00452348","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":628},{"nctId":"NCT00452699","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":621},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT00144911","phase":"PHASE4","title":"ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":740},{"nctId":"NCT00296530","phase":"PHASE4","title":"Study Of Patients With Allergic Rhinitis And Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":600},{"nctId":"NCT00400608","phase":"PHASE4","title":"A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Asthma","enrollment":28},{"nctId":"NCT00346749","phase":"PHASE4","title":"ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":180},{"nctId":"NCT00369993","phase":"PHASE2","title":"Spacer Comparison In Adult Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Asthma","enrollment":20},{"nctId":"NCT00118690","phase":"PHASE4","title":"A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12","conditions":"Bronchospasm, Activity/Exercise Induced Bronchospasm","enrollment":227},{"nctId":"NCT00169546","phase":"PHASE4","title":"Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Asthma","enrollment":64},{"nctId":"NCT00920959","phase":"PHASE3","title":"Advair Pediatric Once-Daily","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-11","conditions":"Asthma","enrollment":908},{"nctId":"NCT00370591","phase":"PHASE4","title":"Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-12","conditions":"Asthma","enrollment":48},{"nctId":"NCT01908140","phase":"PHASE3","title":"Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":933},{"nctId":"NCT00456313","phase":"PHASE4","title":"No Resistance After Long Term Treatment SERETIDE","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2007-12","conditions":"Asthma","enrollment":""},{"nctId":"NCT01712451","phase":"PHASE2","title":"Dose-ranging Study","status":"COMPLETED","sponsor":"Neothetics, Inc","startDate":"2011-08","conditions":"Abdominal Contour Defects","enrollment":200},{"nctId":"NCT00568347","phase":"","title":"Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange","status":"COMPLETED","sponsor":"Arthur F Gelb MD","startDate":"2006-01","conditions":"COPD","enrollment":39},{"nctId":"NCT01763463","phase":"","title":"WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01681979","phase":"","title":"WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Asthma","enrollment":1},{"nctId":"NCT02094274","phase":"PHASE1","title":"A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2013-11","conditions":"Asthma","enrollment":30},{"nctId":"NCT02136875","phase":"PHASE4","title":"Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2008-07","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":37},{"nctId":"NCT00662805","phase":"","title":"Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":762},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT00557440","phase":"PHASE2","title":"Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Salmeterol"],"phase":"marketed","status":"active","brandName":"Fluticasone Propionate/Salmeterol Combination Product","genericName":"Fluticasone Propionate/Salmeterol Combination Product","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate is a corticosteroid that reduces airway inflammation, while salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}